Last updated: February 24, 2026
What is NDC 70677-1118?
NDC 70677-1118 refers to a specific pharmaceutical product in the U.S. market. Based on available databases, this NDC code corresponds to Azelastine Hydrochloride Nasal Spray, 0.15%, used primarily for allergic rhinitis and conjunctivitis treatments.
Market Size and Sales Trends
Current Market Landscape
- The U.S. prescription market for allergy medications exceeds $4 billion annually.
- Azelastine nasal spray has a market share estimated at 8% within intranasal antihistamines.
- Key competitors include Fluticasone (Flonase), Mometasone (Nasonex), and other antihistamines.
Sales Data (2022–2023)
| Year |
Estimated Sales (USD millions) |
Market Share (%) |
Growth Rate (%) |
| 2022 |
320 |
8 |
4 |
| 2023 |
330 |
8.2 |
3.1 |
Source: IQVIA, 2023.
Market Dynamics
- Increased prevalence of allergic conditions drives steady growth.
- Rising adoption in pediatric and elderly populations.
- Growth in OTC sales is limited due to prescription-only status.
Pricing Analysis
Current Pricing
- Average wholesale acquisition cost (AWAC): approximately $18 per 60-dose spray.
- Retail pharmacy price: varies between $25 and $35 per bottle.
- Insurance reimbursement largely covers branded and generic formulations equally.
Cost Trends
- Prices have remained relatively stable since 2020.
- Competitive pressures from generics began in 2021, reducing prices by approximately 15% across the board.
Price Projections (Next 3 Years)
| Year |
Estimated Price Range (per bottle) |
Influencing Factors |
| 2024 |
$20–$28 |
Increased generic competition, inflation concerns |
| 2025 |
$22–$30 |
Market saturation limits pricing power |
| 2026 |
$23–$31 |
Potential price erosion with patent expiration (if applicable) |
Key Factors Affecting Price Movements
- Patent status: No patent expiration is currently scheduled.
- Competition: Entry of biosimilars or advanced delivery devices could pressure prices.
- Regulatory changes: New policies promoting generic substitution could reduce prices further.
- Manufacturing costs: Slight increases in raw material prices may push prices upward incrementally.
Regulatory and Patent Status
- The patent for Azelastine nasal spray expired in the U.S. in 2021.
- Generic versions are marketed by multiple manufacturers.
- No current legal barriers prevent new generic entrants.
Competitive Landscape
| Product Name |
Brand/Generic Status |
Market Share (%) |
Price Range (USD) |
Notes |
| Azelastine nasal spray |
Generic |
8.2 |
$25–$35 |
Dominant in prescription segment |
| Fluticasone propionate |
Brand & generic |
25 |
$15–$25 |
Leading intranasal allergen treatment |
| Mometasone furoate |
Brand & generic |
15 |
$20–$30 |
Increasing market penetration |
Strategic Insights
- Entry of new generics intensifies price competition.
- Innovations in delivery (e.g., longer-acting formulations) may command higher prices or market share.
- Market growth depends on broader allergy prevalence trends and insurance reimbursement policies.
Key Takeaways
- The market for azelastine nasal spray remains stable, with modest growth driven by allergy prevalence.
- Prices are expected to stabilize or decrease slightly due to generic competition.
- Future pricing trends will depend on patent status, regulatory changes, and competitive innovations.
- Although current prices are around $25–$35, market pressures could compress prices further in the next few years.
- The absence of patent protection after 2021 indicates a highly competitive generic landscape.
FAQs
1. Is there potential for price increases due to manufacturing costs?
Incremental cost increases could lead to slight price hikes, but significant increases are unlikely given intense generic competition.
2. How will patent expiration affect pricing?
Patent expiration typically reduces prices through generic entry, which is already occurring.
3. Are biosimilars relevant for this drug?
No, biosimilars are generally applicable to biologics; azelastine is a small-molecule antihistamine.
4. How does insurance coverage impact retail prices?
Insurance often covers generics and branded drugs similarly, reducing out-of-pocket costs for patients.
5. What are the main competitors, and how do they compare?
Fluticasone and Mometasone have larger market shares and offer alternative treatment options with similar efficacy but sometimes different formulations or delivery systems.
References
[1] IQVIA. (2023). Prescription Drug Market Data.
[2] FDA. (2021). Patent and Exclusivity Information for Azelastine.
[3] SSR Health. (2022). Pricing Trends for Nasal Allergens.
